Skip to main content
Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

Evaluation of multiple biomarkers to estimate risk of cancer in gynecology patients presenting with a pelvic mass

Research Question:
Can the technology, ParsortixTM PC1 system, help physicians determine whether an abnormal pelvic mass in women is benign (non-cancerous) or malignant (cancerous) using a blood test?

Basic Study Information

Purpose:
The purpose of this study is to validate and refine a technology that can help physicians determine whether an abnormal pelvic mass in women is benign (non-cancerous) or malignant (cancerous) using a blood test. The specific technology is called ParsortixTM PC1 system, a semi-automated system capable of capturing and harvesting rare cells for subsequent analysis from blood based on the size and deformability of the cells.

Location: University of Rochester Medical Center
Study Reference #: IGYN18142

Lead Researcher (Principal Investigator)

Lead Researcher:  Richard Moore

Study Contact Information

Study Coordinator: Laura Mitchell
Phone: (585) 275-7763
Email: Laura_Mitchell@URMC.Rochester.edu

Additional Study Details

Return to Search